Limits...
Prognostic and clinical significance of claudin-4 in gastric cancer: a meta-analysis.

Liu JX, Wei ZY, Chen JS, Lu HC, Hao L, Li WJ - World J Surg Oncol (2015)

Bottom Line: Systematic searches on PubMed, Embase, and Cochrane Library prior to December 2014 were performed.Over-expression of claudin-4 was also associated with advanced stage (OR: 1.96, 95 % CI: 1.08-3.56) and lymphoid node metastasis (OR: 1.72, 95 % CI: 1.05-2.81) of gastric cancer patients.No significant publication bias was found among the studies (P > 0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, No. 1 People's Hospital of Nanning, 89 Qixing Rd, Nanning, 530022, China.

ABSTRACT

Background: The current reports on the association of claudin-4 expression with gastric cancer outcome were inconsistent. Thus, we conducted a meta-analysis to assess the association of claudin-4 expression with the prognosis and clinical parameters more precisely.

Methods: Systematic searches on PubMed, Embase, and Cochrane Library prior to December 2014 were performed. The pooled hazard ratio (HR) with its 95 % confidence interval (95 %CI) was used to assess the prognostic value of claudin-4 expression with gastric cancer patients, and the pooled odds ratio (OR) with its 95 %CI was used to assess the association with clinical parameters.

Results: Nine studies with a total of 1265 gastric cancer patients were included. Overall, the pooled results showed that over-expression of claudin-4 was associated with a poor survival in gastric cancer patients (HR: 2.01, 95 % CI: 1.62-2.50). Over-expression of claudin-4 was also associated with advanced stage (OR: 1.96, 95 % CI: 1.08-3.56) and lymphoid node metastasis (OR: 1.72, 95 % CI: 1.05-2.81) of gastric cancer patients. No significant publication bias was found among the studies (P > 0.05).

Conclusions: This meta-analysis shows that over-expression of claudin-4 is associated with progress of gastric cancer and poor prognosis of gastric cancer patients.

No MeSH data available.


Related in: MedlinePlus

Meta-analysis of claudin-4 expression with clinical stage of gastric cancer
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4481068&req=5

Fig3: Meta-analysis of claudin-4 expression with clinical stage of gastric cancer

Mentions: Seven studies with 1026 patients investigated the association between claudin-4 expression and the tumor stage of gastric cancer. The meta-analysis showed that over-expression of claudin-4 was associated with advanced stage of gastric cancer (OR: 1.96, 95 % CI: 1.08–3.56, P = 0.031), and moderate heterogeneity was found among the studies (I2 = 69.0, P = 0.004). See Fig. 3. The heterogeneity was reduced by removing each study in turn in the sensitivity analysis, and the sensitivity analysis result remained similar to the main result. No significant publication bias was found among the studies (Egger’s test: P = 0.125; Begg’s test: P = 0.293).Fig. 3


Prognostic and clinical significance of claudin-4 in gastric cancer: a meta-analysis.

Liu JX, Wei ZY, Chen JS, Lu HC, Hao L, Li WJ - World J Surg Oncol (2015)

Meta-analysis of claudin-4 expression with clinical stage of gastric cancer
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4481068&req=5

Fig3: Meta-analysis of claudin-4 expression with clinical stage of gastric cancer
Mentions: Seven studies with 1026 patients investigated the association between claudin-4 expression and the tumor stage of gastric cancer. The meta-analysis showed that over-expression of claudin-4 was associated with advanced stage of gastric cancer (OR: 1.96, 95 % CI: 1.08–3.56, P = 0.031), and moderate heterogeneity was found among the studies (I2 = 69.0, P = 0.004). See Fig. 3. The heterogeneity was reduced by removing each study in turn in the sensitivity analysis, and the sensitivity analysis result remained similar to the main result. No significant publication bias was found among the studies (Egger’s test: P = 0.125; Begg’s test: P = 0.293).Fig. 3

Bottom Line: Systematic searches on PubMed, Embase, and Cochrane Library prior to December 2014 were performed.Over-expression of claudin-4 was also associated with advanced stage (OR: 1.96, 95 % CI: 1.08-3.56) and lymphoid node metastasis (OR: 1.72, 95 % CI: 1.05-2.81) of gastric cancer patients.No significant publication bias was found among the studies (P > 0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, No. 1 People's Hospital of Nanning, 89 Qixing Rd, Nanning, 530022, China.

ABSTRACT

Background: The current reports on the association of claudin-4 expression with gastric cancer outcome were inconsistent. Thus, we conducted a meta-analysis to assess the association of claudin-4 expression with the prognosis and clinical parameters more precisely.

Methods: Systematic searches on PubMed, Embase, and Cochrane Library prior to December 2014 were performed. The pooled hazard ratio (HR) with its 95 % confidence interval (95 %CI) was used to assess the prognostic value of claudin-4 expression with gastric cancer patients, and the pooled odds ratio (OR) with its 95 %CI was used to assess the association with clinical parameters.

Results: Nine studies with a total of 1265 gastric cancer patients were included. Overall, the pooled results showed that over-expression of claudin-4 was associated with a poor survival in gastric cancer patients (HR: 2.01, 95 % CI: 1.62-2.50). Over-expression of claudin-4 was also associated with advanced stage (OR: 1.96, 95 % CI: 1.08-3.56) and lymphoid node metastasis (OR: 1.72, 95 % CI: 1.05-2.81) of gastric cancer patients. No significant publication bias was found among the studies (P > 0.05).

Conclusions: This meta-analysis shows that over-expression of claudin-4 is associated with progress of gastric cancer and poor prognosis of gastric cancer patients.

No MeSH data available.


Related in: MedlinePlus